{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T14:22:48Z","timestamp":1781101368975,"version":"3.54.1"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We present an 87-year-old man diagnosed with prostate cancer and neuroendocrine differentiation, posttherapy results to consecutive <jats:sup>177<\/jats:sup>Lu\u2013prostate-specific membrane antigen and <jats:sup>177<\/jats:sup>Lu-DOTATATE. Despite hormonal therapy and chemoradiotherapy, the patient progressed rapidly, and multiple liver and bone metastases showed regression after <jats:sup>177<\/jats:sup>Lu\u2013prostate-specific membrane antigen and <jats:sup>177<\/jats:sup>Lu-DOTATATE treatment. Prostate cancer with neuroendocrine differentiation is resistant to treatments; however, treatment with the combination of <jats:sup>177<\/jats:sup>Lu-DOTATATE therapy may be promising.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005131","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T06:00:34Z","timestamp":1709013634000},"page":"447-448","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Dual 177Lu\u2013Prostate-Specific Membrane Antigen and 177Lu-DOTATATE Therapy in Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation"],"prefix":"10.1097","volume":"49","author":[{"given":"Ediz","family":"Beyhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zge","family":"Erol Fenercio\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahime","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tevfik Fikret","family":"\u00c7ermik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurhan","family":"Erg\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"bib1-20250621","first-page":"90","article-title":"Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure","volume":"5","year":"2015","journal-title":"Front Oncol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/RLU.0000000000002013","article-title":"Adenocarcinoma prostate with neuroendocrine differentiation: potential utility of 18F-FDG PET\/CT and 68Ga-DOTANOC PET\/CT over 68Ga-PSMA PET\/CT","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/RLU.0000000000001618","article-title":"Molecular imaging in neuroendocrine differentiation of prostate cancer","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/RLU.0000000000001424","article-title":"PET\/CT with 68Ga-DOTA-TATE for diagnosis of neuroendocrine: differentiation in patients with castrate-resistant prostate cancer","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1097\/RLU.0000000000002824","article-title":"177Lu-PSMA and 177Lu-DOTATATE therapy in a patient with metastatic castration-resistant prostate Cancer and neuroendocrine differentiation","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/RLU.0000000000002780","article-title":"Excellent response to 177Lu-DOTATATE peptide receptor radionuclide therapy in a patient with progressive metastatic castration-resistant prostate cancer with neuroendocrine differentiation after 177Lu-PSMA therapy","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1097\/RLU.0000000000003685","article-title":"Prostate cancer with neuroendocrine differentiation recurring after treatment with 177Lu-PSMA: a chance for 177Lu-DOTATATE therapy?","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/bju.15621","article-title":"The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol","volume":"130","year":"2022","journal-title":"BJU Int"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:04:35Z","timestamp":1750532675000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005131","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,26]]}}}